Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Oct 15, 2009 (Vol. 29, No. 18)

Protein Ligand Database

URL:www-mitchell.ch.cam.ac.uk/pld/index.html
  • Simple interface, easy navigation
  • Still in development

It’s the touching story of when protein meets ligand: bonded by hydrogen bonds and hydrophobic contacts, the pair can go on to regulate gene expression, facilitate cell signaling, or mediate metabolism. The Protein Ligand Database (or PLD, as insiders in the business like to call it), developed at the University of Cambridge, is a nice database for researchers interested in studying the nature of protein-ligand interactions. Currently containing 485 protein-ligand complexes, the database continues to be expanded. One can search by protein name or function, ligand name or origin (natural product versus xenobiotic), or by interaction type. There are also tools available to view experimental and predicted binding energies. With a simple design, the website is easy to navigate. This is a good resource for researchers that will continue to improve as the database expands.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »